<li>afatinib<p>verapamil increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors.</p></li><li>alosetron<p>verapamil will increase the level or effect of alosetron by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.</p></li><li>amisulpride<p>amisulpride, verapamil.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Prolonged QT interval; risk of torsade de pointes.</p></li><li>astemizole<p>verapamil will increase the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>atenolol<p>verapamil, atenolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>axitinib<p>verapamil increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .</p></li><li>betaxolol<p>verapamil, betaxolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>bisoprolol<p>verapamil, bisoprolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>bosutinib<p>verapamil increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>verapamil increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cisapride<p>verapamil will increase the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>cobimetinib<p>verapamil will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).</p></li><li>cyclobenzaprine<p>verapamil and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>digoxin<p>verapamil increases levels of digoxin by decreasing renal clearance. Avoid or Use Alternate Drug.</p></li><li>dihydroergotamine<p>verapamil will increase the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>dihydroergotamine intranasal<p>verapamil will increase the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>dronedarone<p>verapamil will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>duloxetine<p>verapamil will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.</p></li><li>edoxaban<p>verapamil will increase the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended</p></li><li>eliglustat<p>verapamil increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .</p></li><li>ergotamine<p>verapamil will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>verapamil will increase the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>verapamil will increase the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>verapamil will increase the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>verapamil will increase the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>esmolol<p>verapamil, esmolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>fentanyl<p>verapamil will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl intranasal<p>verapamil will increase the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl iontophoretic transdermal system<p>verapamil will increase the level or effect of fentanyl iontophoretic transdermal system by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl transdermal<p>verapamil will increase the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>fentanyl transmucosal<p>verapamil will increase the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.</p></li><li>ibrutinib<p>verapamil increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ibrutinib with moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition; if unable to avoid, decrease ibrutinib dose to 140 mg/day.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>irinotecan<p>verapamil will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>irinotecan liposomal<p>verapamil will increase the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Observe the patient for development of toxicity associated with verapamil (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of verapamil or withdrawing one of the agents.</p></li><li>ivabradine<p>verapamil will increase the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.</p></li><li>ivacaftor<p>ivacaftor increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.<span><br><br></span>ivacaftor, verapamil.
Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates; reduce ivacaftor dose to 150 mg once daily when coadministered with moderate CYP3A4 inhibitors.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>levobunolol<p>verapamil, levobunolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>lovastatin<p>verapamil will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed 20 mg of lovastatin </p></li><li>metoprolol<p>verapamil, metoprolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>nadolol<p>verapamil, nadolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>naloxegol<p>verapamil will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay</p></li><li>nebivolol<p>verapamil, nebivolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>olaparib<p>verapamil will increase the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg PO BID</p></li><li>pazopanib<p>verapamil will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day</p></li><li>pomalidomide<p>verapamil increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.</p></li><li>propranolol<p>verapamil, propranolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>ranolazine<p>verapamil will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>rifampin<p>rifampin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>riociguat<p>verapamil will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed</p></li><li>sertindole<p>verapamil will increase the level or effect of sertindole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>silodosin<p>verapamil will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>simvastatin<p>verapamil will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not exceed simvastatin 10 mg daily when given concurrently. Potential for increased risk of myopathy/rhabdomyolysis.</p></li><li>sirolimus<p>verapamil will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>sotalol<p>verapamil, sotalol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>terfenadine<p>verapamil will increase the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>timolol<p>verapamil, timolol.
Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.</p></li><li>tizanidine<p>verapamil will increase the level or effect of tizanidine by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug.</p></li><li>tolvaptan<p>verapamil will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.</p></li><li>topotecan<p>verapamil will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance</p></li><li>venetoclax<p>verapamil will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a moderate CYP3A inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.<span><br><br></span>verapamil will increase the level or effect of venetoclax by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.</p></li><li>vilazodone<p>verapamil increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If intolerable adverse effects occur when coadministered with moderate CYP3A4 inhibitors, reduce daily dose to 20 mg.</p></li><li>vortioxetine<p>verapamil increases toxicity of vortioxetine by serotonin levels. Avoid or Use Alternate Drug.</p></li>